The BASE mRNA Facility was founded in 2021 with a mission to provide Australian scientists with rapid and reliable access to high-quality and affordable mRNA.
We help scientists build the next-generation of mRNA vaccines and therapies to treat disease.
The BASE Research laboratories are located at the Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Brisbane.
BASE laboratories include a team of production scientists with state-of-the-art equipment and expertise in the manufacture of mRNA for research use.
We have experience in the discovery and development of novel mRNA vaccines and therapies. We also lead research programs in advanced manufacturing, process development, and development of mRNA platform technologies.
The new BASE Clinical facility will open state-of-the-art GMP clean rooms and laboratories at the Translational Research Institute (TRI) in 2024.
BASE Clinical will develop and manufacture mRNA batches, supported by qualified analytical services, for early stage clinical trials.
BASE Clinical will support Australian scientists advancing mRNA vaccine and therapeutic candidates into the clinic.